On Tuesday, Adverum Biotechnologies Inc (NASDAQ: ADVM) opened lower -10.03% from the last session, before settling in for the closing price of $3.59. Price fluctuations for ADVM have ranged from $2.64 to $10.84 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -54.44% annually for the last half of the decade. Company’s average yearly earnings per share was noted 16.09% at the time writing. With a float of $13.87 million, this company’s outstanding shares have now reached $20.85 million.
In an organization with 155 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -1248.6%, operating margin of -15015.9%, and the pretax margin is -13092.7%.
Adverum Biotechnologies Inc (ADVM) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adverum Biotechnologies Inc is 33.59%, while institutional ownership is 60.69%. The most recent insider transaction that took place on Mar 26 ’25, was worth 102,841. In this transaction 10% Owner of this company bought 20,407 shares at a rate of $5.04, taking the stock ownership to the 125,207 shares. Before that another transaction happened on Mar 27 ’25, when Company’s 10% Owner bought 16,593 for $5.19, making the entire transaction worth $86,089. This insider now owns 141,800 shares in total.
Adverum Biotechnologies Inc (ADVM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 16.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.71% during the next five years compared to 8.03% growth over the previous five years of trading.
Adverum Biotechnologies Inc (NASDAQ: ADVM) Trading Performance Indicators
Check out the current performance indicators for Adverum Biotechnologies Inc (ADVM). In the past quarter, the stock posted a quick ratio of 5.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 67.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.65, a number that is poised to hit -1.94 in the next quarter and is forecasted to reach -3.62 in one year’s time.
Technical Analysis of Adverum Biotechnologies Inc (ADVM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.55 million. That was better than the volume of 0.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.24%. Additionally, its Average True Range was 0.36.
During the past 100 days, Adverum Biotechnologies Inc’s (ADVM) raw stochastic average was set at 17.20%, which indicates a significant decrease from 59.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 94.71% in the past 14 days, which was higher than the 83.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.01, while its 200-day Moving Average is $5.74. However, in the short run, Adverum Biotechnologies Inc’s stock first resistance to watch stands at $3.48. Second resistance stands at $3.74. The third major resistance level sits at $3.89. If the price goes on to break the first support level at $3.07, it is likely to go to the next support level at $2.92. The third support level lies at $2.66 if the price breaches the second support level.
Adverum Biotechnologies Inc (NASDAQ: ADVM) Key Stats
There are currently 20,891K shares outstanding in the company with a market cap of 67.48 million. Presently, the company’s annual sales total 1,000 K according to its annual income of -130,930 K. Last quarter, the company’s sales amounted to 1,000 K and its income totaled -27,130 K.
